ABOUT AXELA
	The People

Jeff Courtney
General Partner
VenGrowth Capital Partners Inc.

Jeff Courtney joined VenGrowth Private Equity Partners Inc. in 2002. He has more than 20 years of experience in the life sciences industry with in-depth expertise across multiple therapeutic areas in quality assurance, regulatory affairs, business development, marketing and sales. Jeff has a proven track record of building organizations and driving revenue growth for both emerging and established life sciences firms - particularly within the sub-verticals of medical devices and pharmaceuticals.

Prior to joining VenGrowth, Jeff was a Partner and Co-President of the Scientific Advisory Board at CDP Capital - Technology Ventures (formerly CDP Sofinov), where he was involved in leading investments in life science companies in Canada and the United States. While at CDP Jeff led investments in Inhibitex Inc., and Intraluminal Therapeutics, and completed secondary financing in Aegera, and Kadmus Pharmaceuticals.

Jeff also served as President of Hospital Pharmaceuticals at Faulding Canada Inc, EVP Marketing and Sales for Pharmascience Inc., as well as 11 years of numerous senior leadership roles with Johnson & Johnson Medical Products. He has served as a Director on the Board of multiple Canadian and US life science companies, including Aegera Therapeutics, Avalon Pharmaceuticals, Exemias Therapeutics, PhageTech Inc. and Inhibitex Inc. He is currently an active board member of VisualSonics Inc., Axela Inc., Zelos Therapeutics Inc., Kadmus Pharmaceuticals Inc. and Metrigenix Inc.

Jeff holds a Bachelor of Science (B.Sc.) in Microbiology from the University of Guelph.

The value that Mr. Courtney brings to Axela includes his strong Life Sciences and therapeutic companyoperating experience, a large network of collaborations, sales and marketing experience and his historical knowledge of Axela as an early investor.